摘要
目的：探讨国产齐拉西酮治疗精神分裂症的疗效及不良反应。方法：将90例精神分裂症患者随机分为齐拉西酮组（30例）、氯氮平组（30例）、利培酮组（30例），进行临床对照试验，三组药物治疗量分别为80～160mg／d、300～600mg／d、4～6mg／d，疗程8周。疗效指标包括阳性和阴性症状量表（PANSS），不良反应指标为不良反应症状量表（TESS）及有关实验室检查。结果：治疗结束时，三组PANSS评分较入组时均显著减低（P〈0．01）。PANSS总减分率：齐拉西酮组为（54．48±10．2）％，氯氮平组为（53．06±11．6）％，利培酮组为（51．76±12．6）％；临床总有效率：齐拉西酮组96．7％，氯氮平组为93．3％，利培酮组93．3％，三组间疗效无显著性差异（P〉0．05）。齐拉西组较氯氮平组、利培酮组不良反应少，对血糖、血脂的影响小。结论：国产齐拉西酮治疗精神分裂症是一种有效、安全的新型非典型抗精神病药。
Objective：To explore domestic Ziprasidone treatment on schizophrenia and the side effects. Methods：Total 90 cases of patients with schizophrenia were randomly divided into Ziprasidone group （30 cases） , Clozapine group （30 cases ） and Risperidone group （ 30 eases ）. Carrying on the clinical check experiment, three groups of medicine therapeutic dose respectively is 80 - 160 mg/d , 300 - 600 mg/d and 4 - 6 mg/d, the treatment course is 8 weeks. Indicators include the effect of positive and negative symptom scale （PANSS）, adverse reactions indicators for adverse reactions Symptom Rating Scale （TESS） and the laboratory. Results： At the end of treatment, three groups＇ PANSS score in the group, were significantly reduced （P 〈 0.01 ）. By PANSS total points： Ziprasidone group （54.48±10.2） % ,Cloapine group （53.06 ± 11.6） %, Risperidone group （51.76 ±12.6） % ; The total efficiency： Zip rasidone group 96.7%, Cloapine group 93.3 %, Risperidone group93.3%. There is no significant difference in the three groups （ P 〉 0.05 ）. But contrast to Clozapine and Risperidone, Ziprasidone has less side reactions and little impact on blood glucose and blood fat. Conclusions： Domestic Ziprasidone is an effective, safe drug, as new atypical antipsyehotic to treat schizophrenia.
出处
《中国民康医学》
2008年第11期1122-1124,共3页
Medical Journal of Chinese People’s Health
